Inflammation as a Therapeutic Target To Improve Vascular Function in Kidney Disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Combined Placental Mesenchymal Stem Cells with Guided Nanoparticles Effective Against Diabetic Nephropathy in Mouse Model.International journal of nanomedicine · 2024
   Article
2. Intervention for early diabetic nephropathy by mesenchymal stem cells in a preclinical nonhuman primate model.Stem cell research & therapy · 2019
   Article
3. Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels.Journal of molecular medicine (Berlin, Germany) · 2019
   Article

Corrections and comments

• Comment on
  IL-1 Inhibition and Vascular Function in CKD.2017

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as